Evidence map›Paper›PMID 33066424›Full record

ArticleCancers2020

Erratum: Mapelli, S.N., et al. A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors).

Sarah N Mapelli, Domenico Albino, Maurizia Mello-Grand, Dheeraj Shinde, Manuel Scimeca, Rita Bonfiglio, Elena Bonanno, Giovanna Chiorino, Ramon Garcia-Escudero, Carlo V Catapano and 1 more

Abstract readPublished Erratum
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Sarah N MapelliInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), 6500 Bellinzona, Switzerland.ORCID 0000-0002-0129-2055
Domenico AlbinoInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), 6500 Bellinzona, Switzerland.
Maurizia Mello-GrandLaboratory of Cancer Genomics, Fondazione Edo ed Elvo Tempia Valenta, 13900 Biella, Italy.ORCID 0000-0003-1041-7590
Dheeraj ShindeInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), 6500 Bellinzona, Switzerland.
Manuel ScimecaDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy.
Rita BonfiglioDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy.
Elena BonannoDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy.
Giovanna ChiorinoLaboratory of Cancer Genomics, Fondazione Edo ed Elvo Tempia Valenta, 13900 Biella, Italy.
Ramon Garcia-EscuderoMolecular Oncology Unit, CIEMAT, 28040 Madrid, Spain.ORCID 0000-0001-5640-6542
Carlo V CatapanoInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), 6500 Bellinzona, Switzerland.ORCID 0000-0002-7079-557X
Giuseppina M CarboneInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), 6500 Bellinzona, Switzerland.ORCID 0000-0003-4652-585X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an error in the title of the paper [...].

Identifiers

PMID33066424
PMCPMC7602137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.